Latest Information Update: 10 Oct 2005
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Mar 2005 Discontinued - Preclinical for Thrombosis in Europe (unspecified route)
- 02 Oct 2003 Preclinical trials in Thrombosis in Europe (unspecified route)